当前位置: X-MOL 学术Parasites Vectors › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe.
Parasites & Vectors ( IF 3.2 ) Pub Date : 2020-03-01 , DOI: 10.1186/s13071-020-3949-y
Csilla Becskei 1 , Julian Liebenberg 2 , Mirjan Thys 1 , Sean P Mahabir 3
Affiliation  

BACKGROUND Tick infestations can cause direct deleterious effects to dogs as a result of tick blood-feeding, and indirectly ticks can transmit disease agents that can be detrimental to the health of both dogs and humans. Six laboratory studies were conducted to support dosage selection and efficacy confirmation of a novel combination of sarolaner, moxidectin and pyrantel against four tick species that commonly infest dogs in Europe. METHODS Two studies were conducted against Dermacentor reticulatus (one of which was a dose determination study), two against Ixodes ricinus, and one each against Ixodes hexagonus and Rhipicephalus sanguineus (sensu lato). In each study, eight purpose-bred Beagle or mix-breed dogs were randomly allocated to each treatment group and infested with 50 unfed adult ticks on Days-2, 5, 12, 19, 26 and 33. On Day 0 dogs were treated orally with placebo or the combination product. In the dose determination study, dogs received sarolaner at point dosages of 0.6 mg/kg, 1.2 mg/kg or 2.4 mg/kg in combination with moxidectin and pyrantel, and in all other studies dogs received Simparica Trio™ to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt). Efficacy was assessed based on live tick counts conducted 48 hours after treatment and each weekly infestation. RESULTS There were no treatment-related adverse events in any study. In the dose determination study, 1.2 mg/kg sarolaner was the lowest dosage evaluated that provided > 90% efficacy for at least 28 days and therefore was selected as the dosage to provide tick control for at least one month following a single oral treatment. In the dose confirmation studies, a single oral dose of Simparica Trio™ provided ≥ 99.2% efficacy against existing infestations of all tick species, and against re-infestations efficacy was ≥ 97.2% against D. reticulatus for 28 days and against all other species for 35 days. CONCLUSIONS These studies support the sarolaner dose selected and confirm the efficacy of a single oral dose of Simparica Trio™ against existing infestations and re-infestations of the common tick species infesting dogs in Europe for at least one month.

中文翻译:

含有sarolaner,moxidectin和pyrantel(Simparica Trio™)的新型咀嚼片对欧洲四种常见tick虫的功效。

背景技术由于虱子的血液喂养,虱子的侵染可能对狗造成直接的有害影响,并且tick的间接传播可以传播对狗和人的健康都有害的疾病因子。进行了六项实验室研究,以支持sarolaner,moxidectin和pyrantel对四种常见于欧洲犬类的壁虱物种的新型组合的剂量选择和功效确认。方法进行了两项针对网状真皮的研究(其中一项是剂量确定研究),两项针对蓖麻短吻线虫,两项针对六头短吻线虫和红头蛇脑线虫(sensu lato)。在每项研究中,将八只专用犬比格犬或混种犬随机分配至每个治疗组,并在第2、5、12、19、26和33天感染50只未喂食的成年s。在第0天,用安慰剂或组合产品口服治疗狗。在剂量确定研究中,犬与莫昔克丁和吡喃酮联合以0.6 mg / kg,1.2 mg / kg或2.4 mg / kg的点剂量使用sarolaner,在所有其他研究中,犬均接受Simparica Trio™的最低剂量为1.2 mg / kg的sarolaner,24 µg / kg的莫昔克丁和5 mg / kg的吡喃盐(以pa酸盐)。根据治疗后48小时和每周一次侵扰的活tick计数评估疗效。结果在任何研究中都没有与治疗相关的不良事件。在剂量确定研究中,评估的最低剂量为1.2 mg / kg的sarolaner,可在至少28天的时间内提供> 90%的功效,因此被选为在单次口服治疗后至少一个月可提供tick控制的剂量。在剂量确认研究中,Simparica Trio™的单次口服剂量对所有壁虱物种的现有侵染提供≥≥99.2%的功效,在28天内对网纹杜鹃和其他所有物种的抗再侵袭功效≥≥97.2%。 35天 结论这些研究支持选择的sarolaner剂量,并证实了单次口服Simparica Trio™可以有效抵抗欧洲现有的常见tick虫感染和再感染至少一个月。
更新日期:2020-03-02
down
wechat
bug